Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813601 | 1.00 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL9178624 | 0.84 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL3244669 | 0.82 | DPP4 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL38666150 | 0.82 | DPP4 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL9514223 | 0.78 | HDAC6 (0.41) | HDAC6HDAC1HDAC2 | |
| SCHEMBL8612678 | 0.78 | HDAC6 (0.41) | HDAC6HDAC1HDAC2 | |
| SCHEMBL9517948 | 0.78 | HDAC6 (0.41) | HDAC6HDAC1HDAC2 | |
| SCHEMBL22762835 | 0.78 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL16440494 | 0.76 | HDAC6 (0.36) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL22718216 | 0.75 | CA14 (0.33) | HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7368572-B2 | Acetylene derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1656348-B1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARM INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC10, HDAC2 | HDAC6 10/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | HDAC1, HDAC10, HDAC2 | HDAC6 10/4885HDAC1 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.